Loading clinical trials...
Loading clinical trials...
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer: A Prospective, Single-arm, Open-label Study
Conditions
Interventions
Camrelizumab
Trastuzumab
+5 more
Locations
1
China
270 Dongan Road, Fudan University Shanghai Cancer Center
Shanghai, China
Start Date
January 1, 2022
Primary Completion Date
January 1, 2024
Completion Date
January 1, 2025
Last Updated
January 14, 2022
NCT06662786
NCT06663319
NCT05239741
NCT05770102
NCT04812912
NCT06778382
Lead Sponsor
Fudan University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions